Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management Reduces Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management trimmed its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 4.7% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,385,731 shares of the company's stock after selling 67,612 shares during the period. Teva Pharmaceutical Industries makes up approximately 3.4% of Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management's portfolio, making the stock its 11th biggest position. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management owned approximately 0.12% of Teva Pharmaceutical Industries worth $24,971,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Atria Investments Inc increased its position in Teva Pharmaceutical Industries by 135.4% in the 3rd quarter. Atria Investments Inc now owns 30,856 shares of the company's stock valued at $556,000 after buying an additional 17,746 shares in the last quarter. Greenwood Capital Associates LLC bought a new stake in Teva Pharmaceutical Industries in the 3rd quarter valued at about $4,267,000. Catalyst Capital Advisors LLC bought a new stake in Teva Pharmaceutical Industries in the 3rd quarter valued at about $2,019,000. National Pension Service increased its position in Teva Pharmaceutical Industries by 107.3% in the 3rd quarter. National Pension Service now owns 3,170,640 shares of the company's stock valued at $57,135,000 after buying an additional 1,640,940 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. increased its holdings in Teva Pharmaceutical Industries by 73.9% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 465,032 shares of the company's stock worth $8,380,000 after purchasing an additional 197,585 shares in the last quarter. 54.05% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock traded down $0.39 during trading on Friday, hitting $17.11. The company's stock had a trading volume of 6,225,171 shares, compared to its average volume of 6,402,547. The company has a market cap of $19.38 billion, a PE ratio of -20.13, a P/E/G ratio of 1.33 and a beta of 0.87. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 2.57. The business has a fifty day moving average of $17.94 and a 200-day moving average of $17.15. Teva Pharmaceutical Industries Limited has a 52 week low of $8.55 and a 52 week high of $19.31.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. JPMorgan Chase & Co. boosted their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a "neutral" rating in a report on Monday, October 21st. UBS Group boosted their price objective on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a "buy" rating in a report on Tuesday, September 3rd. Barclays boosted their price objective on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an "overweight" rating in a report on Wednesday, October 23rd. Finally, StockNews.com raised Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a report on Thursday, October 17th. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $19.67.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.